Metabolic benefits are further supported through a study in humans indicating that use of Dipeptidyl peptidase 4 (DPP4) inhibitors and/or GLP-1 mimetics are associated with a lower rate of PD compared to other oral antidiabetic drugs (Brauer et al., 2020). Here, GLP1R is linked to Parkinson disease.